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Abstract
Background: Type I pleuropulmonary blastoma (PPB) and congenital cystic adenomatoid malformation of the lung
(CCAM) are cystic lung diseases of childhood. Their clinical and radiological presentations are often similar, and
pathologic discrimination remains difficult in many cases. As a consequence, type I PPB and CCAM are frequently
confused, leading to delayed adequate management for type I PPB. Recent studies have suggested a role for
fibroblast growth factor (FGF) 10 signal pathway in CCAM pathogenesis. The objective of our study was to
determine whether FGF10 signaling differs between CCAM and type I PPB.
Methods: Immunohistochemical studies were performed for expression of FGF10, its receptor FGFR2b, and its inhibitor
sonic hedgehog (SHH) in focal type I PPB (n=6), CCAM type I (n=7), CCAM type II (n=7), and control lungs (n=5).
Results: FGF10, FGFR2b, and SHH expressions differed markedly between type I PPB and both types of CCAM. Type I
and type II CCAM cystic walls expressed FGF10, FGFR2b, and SHH, whereas staining was absent or poor in type I PBB
cystic walls. Expression of FGF10, FGFR2b, and SHH did not differ between CCAM cystic walls and control airway walls.
Conclusions: These findings show that immunohistochemistry with FGF10, FGFR2b, or SHH could be useful in
differentiating CCAM from type I PPB, when a child presents with a focal cystic lung lesion. The absence of strong
expression of FGF10, FGFR2b, and/or SHH makes the diagnosis of CCAM very doubtful.
Keywords: Pleuropulmonary blastoma, Congenital cystic adenomatoid malformation, Lung malformation, Cystic lung
disease, Fibroblast growth factor 10, Children
Introduction
Type I pleuropulmonary blastoma (PPB) and congenital
cystic adenomatoid malformation of the lung (CCAM)
are cystic lung diseases occurring in neonates or in
young children [1]. Distinguishing between them re-
mains a challenge for pathologists, and type I PPB is cur-
rently confused with CCAM [2-4]. PPB is a rare and
aggressive embryonic tumor of the lung [5], which is be-
lieved to arise from primitive lung mesenchyme [6]. PPB
is classified into 3 types: purely cystic (type I), cystic and
solid (type II), and predominately solid (type III) [7].
These 3 types represent different stages of one malignant
process in which type I PPB is the earliest manifestation.
Without complete resection, low-grade cystic PPB (type I)
is likely to progress over 2–4 years to a high grade solid
disease (type III) [6]. Delayed recognition or failure to re-
sect type I PPB significantly worsens prognosis. Overall
survival rate in PPB ranges from 80-85% for type I to 45-
50% for type III [8,9].
CCAM is the most frequent congenital cystic lung le-
sion [10]. Classification of CCAM is based on pathologic
features, type I and type II CCAM being the most fre-
quent forms [11,12]. Type I CCAM is composed of single
or multiple large cysts, while type II CCAM is character-
ized by multiple small cysts. After resection CCAM does
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not recur, and malignant transformation is an unresolved
question, but seems to be an unusual event [10].
Distinguishing between type I PPB, and type I or type
II CCAM is crucial since their management and progno-
sis are different. As these 2 entities share similar clinical
and radiological features, pathologic examination is the
only means to establish the final diagnosis [6,8,9]. However,
the pathologic diagnosis is itself often difficult, because of
the absence of pathognomonic markers that differentiate
between these two cystic diseases. Indeed, CCAM and type
I PPB have many overlapping pathologic features, such as
multiloculated cysts lined with flattened or cuboidal epi-
thelial cells, and imperceptible transition between normal
and pathologic areas [2,4,6,8]. Histologic features of type I
PPB are themselves heterogeneous, with wide variations
regarding the septal cellularity density, the presence of dif-
ferentiated skeletal muscle or cartilage, and the capillary
vessel density [8]. None of these features are specific, in-
creased cell proliferation [13] and striated muscle cells pro-
liferation [14] being described in CCAM. Mainly, foci of
dense subepithelial or septal spindle cell proliferation,
which are highly suggestive of type I PPB [5,8,15], can be
extremely localized [9], making an extensive sampling of
cyst walls critical for diagnosis [15].
The pathogenesis of CCAM is uncertain. Altered ex-
pression of factors controlling normal lung development
has been identified in CCAM [12,15-18]. In particular,
the potential role of fibroblast growth factor (FGF) 10 in
CCAM pathogenesis was recently highlighted [18]. In-
duction of localized lung FGF10 overexpression in fetal
rats resulted in localized macrocystic or microcystic lung
malformations, depending on the developmental stage
and the site of overexpression [18]. FGF10 is a mesen-
chymal growth factor which may act on the epithelium
through its receptor FGFR2b to control pulmonary mor-
phogenesis [19]. It is known to play a key role in branching
morphogenesis [20]. During lung development, mesenchy-
mal FGF10 expression is inhibited by Sonic Hedgehog
(SHH), a diffusible factor secreted by epithelial cells [19].
In this study, we performed immunohistochemical staining
to compare the expression of FGF10, FGFR2b, and SHH
in type I and type II CCAM, and in type I PPB. The objec-
tive was to determine if they were differentially expressed.
Materials and methods
Patients
This study was approved by an Ethics Committee (Comité
de Protection des Personnes, Ile-de-France VII). First part
of the study was conducted from tissue specimens already
collected. Tissues of patients with type I PPB (n=3), and
with CCAM (type I, n=5; type II, n=5) were part of the
archives of the department of pathology of the Necker-
Enfants Malades hospital. Three supplementary speci-
mens of patients with type I PPB were provided by the
departments of pathology of the Centre Hospitalier Re-
gional Universitaire of Lille (n=1), and by the Centre
Hospitalier Universitaire Felix Guyon of La Reunion
(n=2), respectively. The results obtained from CCAM tis-
sues were then prospectively confirmed on four new cases
with CCAM (2 type I and 2 type II), who were operated at
Necker-Enfants Malades Hospital. All patients (n=20)
presented with focal cystic lung lesions, and tissues were
obtained after surgical resection. All CCAM cases were di-
agnosed prenatally, contrasting with none of the PPB
cases. Cases of CCAM evaluated in this study can be
considered as representative, because our center does
not select surgical indications, but proposes a systematic
removal of all congenital lung malformations with cystic
appearance, because of an unpredictable risk of malig-
nancy. Controls were also performed with normal lung
sections (n=5), provided by the department of pathology
of the Raymond Poincare Hospital, Garches, France. These
sections were collected at autopsies of age-matched chil-
dren who died of a non-pulmonary cause (sudden infant
death syndrome). All tissues were obtained from 2006 to
2013. General characteristics of patients are summarized
in the Table 1.
Diagnostic criteria
CCAM and type I PPB were diagnosed after microscopic
examination of surgically excised cystic lesions. CCAM
was classified according to the Stocker classification into
macrocystic type I when cyst size was > 2 cm, and micro-
cystic type II when cyst size was < 2 cm [12]. In the text,
the term “CCAM” will refer to both type I and type II
CCAM. If data are specific to a given type, this one will be
mentioned. Diagnosis of type I PPB was made if one or
more foci of dense subepithelial or septal primitive spindle
cells were present. The initial diagnosis of CCAM and PPB
was confirmed before any staining by the two independent
pathologists participating to this study (VK and JCF).
Immunohistochemistry
After resection, tissues were paraffin-embedded, and 5 μm
sections were cut for immunohistochemistry. Sections were
deparaffinized, rehydrated, and antigens were unmasked by
boiling for 30 minutes in 10 mM citric acid buffer pH 6,
FW: 210,1 (Sigma, Saint-Louis, USA). After 25-minute
cooling at room temperature (RT), sections were rinsed
twice, 5 minutes each, in phosphate-buffered saline (PBS),
pH 7.4 (Life technologies, Carlsbad, USA), and blocked
with 2.5% normal horse serum (RTU Vectastain, Vector
Laboratories, Burlingame, USA) for 15 minutes at RT.
Sections were then incubated overnight at 4°C with the
primary antibodies (FGF10, mab345, R&D Systems, 1:1250;
FGFR2b, ab58201, Abcam, 1:400; SHH, ab53281, Abcam,
1:100), and controls (control FGF10, mab004, R&D Sys-
tems, 1:1250; control FGFR2b, 550878, BD Pharmingen,
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1:100; control SHH, R&D Systems, Ab105/c, 1:1000) , with
1.5% normal horse serum (RTU Vectastain, Vector Labora-
tories, Burlingame, USA) in PBS. After overnight incuba-
tion, sections were washed 3 times in PBS, 2 minutes each,
and endogenous peroxidase was quenched with 3% H202
for 20 minutes at RT. Sections were rinsed 3 times in PBS,
2 minutes each, and then incubated with biotinylated
universal secondary antibody (RTU Vectastain, Vector
Laboratories) for 10 minutes at RT. After 1 wash in PBS,
sections were incubated with the streptavidin-peroxidase
complex from the RTU Vectastain (Vector Laboratories,
Burlingame, USA) for 5 minutes at RT, and rinsed once
for 5 minutes in PBS. Staining was visualized with dia-
minobenzidine (Vector novaRED, Vector Laboratories,
Burlingame, USA) for 10 minutes, and then rinsed with
distilled water for 5 minutes. Sections were counterstained
with hematoxylin for 20 seconds (Hematoxylin QS, Vector
Laboratories, Burlingame, USA). Immunostainings with
Desmin (M0760, Dako, 1:200) and Ki-67 (M7240, Dako,
1:100) were also performed routinely in each type I PPB,
in 7 CCAM, and all controls.
Analysis
The analysis of staining was blinded, and was performed
independently by two of the authors (GL and SV). The
quantification was performed per area of tissue. Because
of their diffuse expression within the interstitial tissue,
FGF10 and SHH staining were analyzed in a descriptive
way, and no reliable quantification could be performed.
By contrast, the localized expression of FGFR2 within
the epithelium allowed a quantitative analysis. For each
patient with type I PPB, CCAM, and normal lung, we
photographed, at magnification 20, five randomized zones
of epithelium stained with FGFR2b and five randomized
zones stained with control antibody. Expression of FGF
R2b/control in epithelial cells was quantified in gray inten-
sity by epithelium area using image J software. Mean values
for control antibody were determined and served as a refer-
ence. They were subtracted from mean values of FGFR2b,
and the resulting values were compared using the nonpara-
metric Mann–Whitney test, and a p value < 0.05 was con-
sidered significant.
Results
FGF10 expression
FGF10 was strongly expressed within the interstitial tis-
sue and the epithelium of airways and alveoli, both in
control lungs and in CCAM (Figure 1). No difference
was observed between controls and CCAM. In CCAM,
all cysts were strongly stained, and no difference was
found between type I and type II lesions.
In contrast, type I PPB was clearly differentiated from
control lungs or CCAM (Figure 1). FGF10 expression was
weak or absent in type I PPB, and was only found in the
interstitial tissue.
FGFR2b expression
In normal lung, FGFR2b was strongly expressed within
the bronchial and bronchiolar epithelium, without any
disruptions (Figure 2). FGFR2 expression was also ob-
served in alveolar type II epithelial cells (not shown). In
CCAM, FGFR2b was strongly expressed in epithelial cells
lining the cysts, whatever the size of the cyst. When consid-
ering the expression per unit epithelial surface, there were
no differences in FGFR2b expression between normal lungs
and type I or type II CCAM (Figure 3). FGFR2b expression
differed significantly between type I PPB and CCAM. Cysts
were not or poorly stained in type I PPB. FGFR2b epithelial
expression was absent from most parts of the lesion, and
was only present focally weakly in a few small cystic areas.
In 2 patients (nos. 17–18), a mild and discontinuous FGF
R2b expression was present in the epithelium lining cysts,
Table 1 General characteristics of cases
N°
Patient
Final diagnosis Age at tissue
collection (months)
Localization
1 CCAM type I 0.1 Right upper lobe
2 CCAM type I 0.2 Right lobe
3 CCAM type I 0.8 Right middle lobe
4 CCAM type I 21.9 Right lobe
5 CCAM type I 42.5 Right upper lobe
6 CCAM type I 6.7 Left inferior lobe
7 CCAM type I 13.6 Left upper lobe
8 CCAM type II 1.8 Left lobe
9 CCAM type II 6.8 Left upper lobe
10 CCAM type II 8.9 Left upper lobe
11 CCAM type II 14.2 Left lobe
12 CCAM type II 15.6 Unknown
13 CCAM type II 1.7 Left inferior lobe
14 CCAM type II 8.8 Right middle lobe
15 PPB type I 31.3 Fowler lobe
16 PPB type I 28.1 Left lobe
17 PPB type I 24.7 Left lobe
18 PPB type I 6.8 Left upper lobe
19 PPB type I 35.6 Left inferior lobe
20 PPB type I 14.8 Unknown
21 Sudden infant death 0.7
22 Sudden infant death 2.5
23 Sudden infant death 4
24 Sudden infant death 7.5
25 Sudden infant death 10.5
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with large parts of the epithelium without FGFR2b staining
(Figure 2D).
After quantification, the intensity of FGFR2b expres-
sion was significantly higher in CCAM, in comparison
with type I PPB (p < 0.002, Figure 3).
SHH expression
In normal lungs, SHH was strongly expressed in both
the bronchial and bronchiolar epithelium, and within
the underlying mesenchyme (Figure 4). A strong expres-
sion of SHH was also present in CCAM, in both the
Figure 1 Immunostaining with FGF10. From left to right, original magnification x 5 (A, C, E, G), x 40 (B, D, F, H). The x40 magnified area is
identified by a rectangle. Counterstain: hematoxilin. A-B: Control lung; strong FGF10 expression in both the epithelium and the underlying
mesenchyme of normal bronchi. C-D: CCAM; the expression of FGF10 is strong and continue within the epithelium lining cysts, and within the
underlying mesenchyme. E-F: multiloculated cysts in type I PPB, G-H: large cyst in a type I PPB; nearly absence of FGF10 expression in type I PPB.
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epithelium and the mesenchyme. The expression of
SHH was continue within the epithelium lining cysts.
Conversely, SHH was virtually not expressed in type I
PPB. Its expression was restricted to the epithelium, and
was weak and discontinuous.
Desmin and Ki-67 expressions
To better characterize analyzed tissues, desmin and Ki-
67 expression were analyzed. In normal lungs, desmin
was expressed in smooth muscle cells surrounding the
bronchi and bronchioles (Figure 5). In CCAM, desmin
Figure 2 Immunostaining with FGFR2b. From left to right, original magnification x 5 (A, C, E, G), x 40 (B, D, F, H). The x 40 magnified area is
identified by a rectangle. Counterstain: hematoxilin. A-B: Control lung; strong FGFR2b expression in epithelial cells of normal bronchi. C-D: CCAM;
strong and continuous FGFR2b expression in the epithelium lining the cysts. E-H: Multiloculated cysts in type I PPB: No staining (E-F) or focal
staining (G-H) for FGFR2b.
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was also expressed in fusiform smooth muscle cells under
the sub-epithelial basement membrane. In type I PPB,
desmin was expressed in small undifferentiated mesenchy-
mal cells within the cystic walls.
Ki-67 expression was absent in normal lungs (Figure 6).
Ki-67 expression was present in both CCAM and type I
PPB cystic walls. It was localized in scattered mesenchy-
mal cells in CCAM, and was present in mesenchymal
cells of the cystic walls in type I PPB.
Discussion
Because of many common histological aspects, type I PPB
is frequently mistaken for CCAM, leading to delayed ap-
propriate treatment for PPB. In addition, there are contra-
dictory statements concerning the origin of these two
lesions. Some support a common origin, making CCAM
able to transform into PPB [21,22]. In contrast, others are
in favor of two separate lesions, without natural evolution
between them [6]. As the FGF10 signaling pathway was
previously suggested to be important in the occurrence of
CCAM [18], the objective of our study was to determine
whether FGF10, FGFR2b, and SHH expressions differed
between CCAM and type I PPB. Our results show that
FGF10, FGFR2b, and SHH are strongly expressed in
CCAM, but not in type I PPB. These findings suggest that
use of immunohistochemistry with these markers could
improve the recognition of type I PPB. The absence of a
strong continuous expression of FGF10, FGFR2b, and SHH
in a focal cystic lung lesion renders the diagnosis of CCAM
very doubtful. Moreover, our results suggest that different
molecular pathways are involved in the development of
these two lesions, and are not in favor of their common
origin.
Preoperatively, congenital cystic lesions are most com-
monly anticipated as being CCAM, and type I PPB is
rarely suspected [8]. Some clinical features associated with
cystic lung lesions can be helpful to suspect a type I PPB
[6,8]. Risk factors for PPB include pneumothorax at pres-
entation, bilateral or multifocal lung cysts, familial lung
cysts, and associated conditions in patient or family such
as renal cystic disease, small bowel polyps, and additional
childhood cancer [6]. However, these clinical features lack
specificity and are often misinterpreted. In their retro-
spective analysis of 51 patients with type I PPB, Hill et al.
found that type I PPB was never suspected preoperatively
despite the high rate of pneumothorax at presentation,
and/or multiple lesions in the lung [8].
CCAM and type I PPB share many microscopic fea-
tures. As in type I PPB, CCAM is often multicystic
[12,23]. In both pathologies, cysts are lined by a benign-
appearing epithelium. There is no specific aspect of the
epithelium that differentiates type I PPB from CCAM.
Flattened, cuboidal, columnar, or ciliated type epithelia
are all observable in both lesions [8,12]. The most spe-
cific microscopic feature of type I PPB is the presence of
primitive malignant spindle cells within the septa. These
mesenchymal cells are absent in CCAM. Their recogni-
tion is crucial and depends on the experience of the exam-
iner since these cells may be extremely localized in small
mesenchymal foci, or present only in small amounts. An
extensive sampling of the cyst walls remains critical for
detailed examination because these cells may only be
present in a few sections. The absence of a total resection
of a cystic lesion may therefore delay type I PPB diagnosis,
and worsens the child’s prognosis.
Cell characterization analyses have been performed in
PPB. Markers that have been tested include desmin,
myogenin, muscle-specific actin, cytokeratin, thyroid tran-
scription factor 1, and S100 protein [2,5,24]. These studies
highlighted the presence of mesenchymal components in
type I PPB, but contributed poorly to type I PPB diagnosis
[5,8,24]. In particular, rhabdomyomatous dysplastic changes
have been also described in CCAM [14,25]. Our study con-
firmed that desmin expression was present in CCAM.
Similarly, we confirmed that increased cell proliferation was
not specific of malignant lesions, but was also present in
CCAM [26]. In contrast, we show that immunohistochem-
istry with FGF10, FGFR2b, and SHH could be useful in dis-
criminating between type I PPB and CCAM. The absence
of a strong expression of FGF10, FGFR2b, and SHH in a
cystic lung lesion makes the diagnosis of CCAM very
doubtful, and should prompt the examiner to search for
foci of abnormal spindle cells and to ensure the surgical re-
section is complete. Routine evaluation of FGF10 signaling
in focal cystic lung lesions of childhood could therefore
Figure 3 FGFR2b intensity by area (mm2), in arbitrary units.
Each point represents the mean of 5 measurements of intensity per
randomized area. For CCAM: closed symbols = type I CCAM ; open
symbols = type II CCAM; circles = retrospective cases; triangles =
prospective cases.
Lezmi et al. Orphanet Journal of Rare Diseases 2013, 8:130 Page 6 of 11
http://www.ojrd.com/content/8/1/130
markedly reduce the risk of confusion between CCAM and
type I PPB, and increase the recognition of type I PPB.
The results of our study support the assumption that
type I PPB and CCAM are two distinct diseases. FGF10
signaling is known to play a key role in normal branching
morphogenesis [20]. FGF10, FGFR2b, and SHH are nor-
mally expressed in the fetal lung mesenchyme and airway
epithelium, respectively [18]. In the present study, we dem-
onstrate a persistent expression of FGF10, FGFR2b, and
SHH in the normal postnatal lung (airways and alveoli).
Figure 4 Immunohistochemistry with SHH. From left to right, original magnification x 5 (A, C, E, G), x 40 (B, D, F, H). The x 40 magnified area is
identified by a rectangle. Counterstain: hematoxilin. A-B: Control lung; Strong expression of SHH in both the epithelium and the underlying
mesenchyme of normal bronchi. C-D: CCAM. The expression of SHH is strong and continue within the epithelium lining cysts, and within the
mesenchyme. E-G: type I PPB: No SHH staining within the mesenchyme; Focal staining (E-F) or no staining (G-H) in the epithelium lining the cysts.
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Postnatal FGF10 signaling pathway have been poorly previ-
ously described in postnatal lungs. In rodents, FGF10
mRNA expression was demonstrated to be persistent in
adult rats lungs [27]. Similarly, FGFR2 mRNA expression
was demonstrated in adult mice lungs [28]. In humans,
Jancelewicz et al. found a low level of FGF10 mRNA ex-
pression in infant lungs [29], whereas Hughes found that
FGFR2b was strongly expressed in respiratory epithelium
of adult lungs [30]. So there is concordance between ani-
mal and human data to confirm the persistence of lung ex-
pression of FGF10 and FGFR2b through adulthood. As a
result, the slight age difference between our PPB and
CCAM cases cannot explain the observed differences in
FGF10 signaling. The exact role for this pathway in the
postnatal lung remains unknown. Since FGR2b expression
is predominant in the airway epithelium, the FGF10
signaling pathway may be involved in airway homeostasis.
In this connection, it was recently demonstrated that gen-
etic variants affecting the FGF10 signaling pathway were
important determinants of adult lung function that may ul-
timately contribute to chronic obstructive pulmonary dis-
ease [31]. Among other FGFs, FGF7 also binds specifically
to FGFR2b [32]. Despite binding to the same receptor iso-
form, these two growth factors do not share the same role
in normal lung development. FGF-10 null mice have strik-
ing abnormalities, including total absence of lung develop-
ment below the trachea [33], whereas FGF7 null mice had
histologically normal lung development and survival [34].
In our study, the parallel demonstration of major differ-
ences in expression of SHH, which is a powerful negative
regulator of FGF10 in branching morphogenesis, strengthen
our conclusions on differences in FGF10 signaling between
Figure 5 Immunohistochemistry with desmin. From left to right, original magnification x 10 (A, C, E), x 40 (B, D, F). The x 40 magnified area is
identified by a rectangle. Counterstain: hematoxilin. A-B: Control lung; expression of desmin in smooth muscle cells surrounding normal bronchi.
C-D: CCAM; expression of desmin in smooth muscle cells underlying the sub-basement membrane of the epithelium ling cyst. E-F: type I PPB;
desmin expression in mesenchymal cells of the cystic wall.
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CCAM and PPB. Moreover, because FGF10, FGFR2b, and
SHH expressions in cystic walls of CCAM do not differ
from expression in control airway walls, this strongly
suggests that CCAM results from an abnormal enlarge-
ment of initially normal airways. Such absence of differ-
ence in FGF10 signaling between control postnatal lungs
and CCAM lungs was previously demonstrated at the
mRNA level [29]. By contrast, the absence of FGF10,
FGFR2b, or SHH in cystic walls of PPB suggests that this
lesion does not derive from normal airways. These find-
ings may suggest that CCAM and type I PPB are pheno-
typically different from the early stage of their origin, and
that PPB is not a malignant transformation of CCAM. We
can, however, not completely exclude that the absence
of FGF10, FGFR2b, or SHH does not correspond to a cell
dedifferentiation following malignant transformation. This
hypothesis seems, however, very unlikely for two main
reasons. First, PPB is believed to arise from primitive
lung mesenchyme, suggesting that the observed epithe-
lial phenotype is the original one. Second, in the case of
dedifferentiation, we would expect foci of normal and
dedifferentiated cystic walls. This was not observed in
our PPB cases, although some epithelial cells lining PPB
cysts in two cases had identifiable FGFR2b or SHH ex-
pression. The hypothesis of a distinct origin for CCAM
and PPB is consistent with previous cytogenetic studies.
The comparison of the karyotype between 11 CCAM
cases with 2 PPB cases demonstrated clonal abnormalities
in both the PPB cases, but in none of the CCAM cases
[35]. Similarly, CGH analysis of 5 PPB cases (1 type I, 2
type II, 2 type III) evidenced gain or loss of chromosomal
materials in all cases [36]. In CCAM, chromosomal
Figure 6 Immunohistochemistry with Ki-67. From left to right, original magnification x 10 (A, C, E), x 40 (B, D, F). The x 40 magnified area is
identified by a rectangle. Counterstain: hematoxilin. A-B: Control lung; absence of Ki-67 expression. C-D: CCAM; Ki-67 is expressed in scattered
mesenchymal cells. E-F: type I PPB; Ki-67 expression in mesenchymal cells within the cystic wall.
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aberrations may occasionally be detected, in cases associ-
ated with foci of atypical goblet cell hyperplasia, adenoma-
tous hyperplasia or adenocarcinoma [37].
Our study has some limitations. Because of the rarity
of PPB, the number of evaluated patients remains low.
Although the constancy of FGF10 signaling in CCAM is
clearly demonstrated, the difference we found between
type I PPB and CCAM should be further prospectively
confirmed.
In conclusion, our study shows that the absence of
strong expression of FGF10 signaling in surgically excised
cystic lung lesions from children makes the diagnosis of
CCAM very doubtful. Evaluation of FGF10, FGFR2b, and/
or SHH expression in these lesions may therefore reduce
the risk of confusion between type I PPB and CCAM.
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